Zoekresultaten - 5 results
Interim analysis of COVID-19 vaccine effectiveness against hospitalisation and death using electronic health records in six European countries
a monthly basis, using a study period covering an eight-week follow-up period. Each month the study period was shifted forward to the following month. Country estimates were then pooled together. The study ...
Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022.
construct population cohorts in Belgium, Denmark, Luxembourg, Navarre (Spain), Norway and Portugal. Using a common protocol, for each outcome, VE was estimated monthly over 8-week follow-up periods, allowing ...
Vaccine effectiveness of the second and third COVID-19 boosters in Belgium (administered during 2022 autumn campaign)
COVID-19 was rolled out to the adult population in Belgium, followed by the first booster campaign towards the end of the year. At the beginning of 2022, booster doses were recommended and offered to people ...
Regulatory issues regarding manufacture and control of vaccine adjuvants. The EU situation.
on adjuvants describes all the quality requirements, where the adjuvant should fulfil to. Depending on the type of adjuvant, additional guidelines are in force and should be followed. Non clinical ...
Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays.
Vaccine, Inactivated Poliovirus Vaccine, Oral Vaccine Potency Vaccines, Attenuated Abstract: BACKGROUND: Following the declaration of wild-type 2 poliovirus eradication in 2015, the type 2 component was ...